U.S. Pharma Stock News

In recent trading, Everus Construction Group was caught in a past broad selloff across the engineering and construction sector, with investors rotating away from the space as peers also weakened. The steeper reaction in Everus shares compared with sector peers hints at investor sensitivity to sector-wide swings, even without fresh company-specific developments. We’ll now examine how this sector-wide pressure on engineering and construction stocks could influence Everus Construction Group’s...

Abercrombie & Fitch (ANF) is in focus after opening a new SoHo flagship alongside aggressive summer promotions, including sitewide discounts and targeted offers, moves that spotlight how management is thinking about customer growth and brand reach. See our latest analysis for Abercrombie & Fitch. Investors have watched momentum pick up again recently, with a 14.56% 7 day share price return and 29.09% 30 day share price return, even as the year to date share price return is down 26.38%. At the...

Tenet Healthcare recently attracted attention after analysts raised earnings estimates for the year, highlighting a projected 4.9% increase in EPS and stronger expected cash flow growth than the broader industry. This combination of upward estimate revisions, a favorable Zacks Rank #2, and an A Growth Score reinforces the market’s focus on Tenet’s potential as a growth-oriented healthcare operator. Next, we’ll examine how these upgraded earnings expectations and stronger cash flow prospects...

Chubb (CB) has been drawing attention after recent share price moves, with the stock last closing at US$326.95. For investors, the key question is how this valuation lines up with Chubb’s fundamentals. See our latest analysis for Chubb. While the recent 1-day share price return declined 0.36%, the stock has still recorded a 5.45% share price return year to date and a 15.60% total shareholder return over the past year, suggesting momentum has been broadly positive despite short term...

Recent share performance and business scale JPMorgan Chase (JPM) has attracted attention after recent trading, with the stock last closing at US$319.40. For context, the bank carries a market value of about US$859.4b. Over the past week the share price gained about 2.7%, with a move of roughly 7.2% over the past month and about 11.3% over the past 3 months. Over the past year, the total return is about 20.4%. The group operates across Consumer & Community Banking, Commercial & Investment...

When the Federal Reserve is weighing a more hawkish stance and inflation sits above 4%, stable dividend growth can look appealing, but not all dividend stocks react the same way to rate and inflation headlines. The latest Fed meeting and US Iran peace developments around the Strait of Hormuz may shift expectations for energy prices, inflation, and future policy guidance, which can help or hurt different dividend payers. This article walks through three dividend growth stocks from our screener...

Recent performance snapshot and what it means for IDEX (IEX) IDEX (IEX) has drawn fresh attention after a steady run, with the stock last closing at US$222.04 and total return figures highlighting how the company has been tracking over different holding periods. Over the past month, IDEX shows a 6.9% return, and about 16.6% over the past 3 months, with year to date performance at 24% and a 1 year total return of 25.3%. Longer holding periods show total returns of 10.3% over 3 years and 9%...

If you are wondering whether Moelis stock at around US$69.09 still offers value, or if most of the upside is already reflected in the price, this article breaks down what the current price might be implying about the company. The stock has returned 0.6% over the past week and 8.4% over the past month, while year to date it is down 3.0% but shows a 26.8% return over 1 year, 73.1% over 3 years and 67.5% over 5 years. Recent news coverage of Moelis has focused on the broader interest in capital...

Lululemon athletica (LULU) drew fresh attention after first quarter 2026 results showed revenue of US$2.47b, alongside a lower net income figure and reduced earnings outlook, set against firm international growth and North American pressure. See our latest analysis for lululemon athletica. Lululemon’s share price has fallen 27.04% over the past 90 days and is down 44.87% year to date, while the 1 year total shareholder return has declined 51.84%. This points to fading momentum as earnings...

Target (NYSE:TGT) has appointed designer Isaac Mizrahi as its first creative director at large. Mizrahi will mentor Target's in house design team, guide product development, and support new brand partnerships. The role also includes launching a mentorship program aimed at developing emerging creative talent within the company. For investors watching NYSE:TGT, this move comes with the stock trading at $133.17, after returns of 7.4% over the past week and 9.6% over the past month. The shares...

Earlier this month, One New Zealand Limited announced it had overhauled its complex enterprise mobile provisioning workflow using UiPath Maestro, deploying AI agents and software robots across Salesforce, Oracle, and internal systems to move from multi-day order cycles to near real-time provisioning with greater visibility and control. This rapid five-week rollout, and One New Zealand’s plan to extend Maestro into finance, risk, fraud, IT, and wider operations, underscores how UiPath is...

Investors may be wondering if CECO Environmental at around US$95 per share still offers value, or if most of the opportunity is already priced in. The stock recently closed at US$95.01, with returns of 18.0% over 7 days, 17.5% over 30 days, 58.9% year to date and 224.3% over the past year, while the 3‑year and 5‑year returns are very large. Recent attention on CECO Environmental has centred on its share price strength and how the market is reassessing the company within the broader machinery...

EGFR Market Attention Puts Focus on ArriVent BioPharma Recent commentary on the EGFR inhibitor market, highlighting precision medicine trends and ArriVent BioPharma (AVBP) firmonertinib trials in non small cell lung cancer, has pushed this clinical stage stock back onto investor watchlists. See our latest analysis for ArriVent BioPharma. At a latest share price of US$30.30, ArriVent's short term share price return has been relatively steady. The 30 day share price return of 8.7% and year to...

Everest Group Ltd. recently appointed Peter Chalkias as Australia country head and chief financial officer, bringing expertise in financial risk, risk management, accounting, financial planning, and business process improvement to its expanding international operations. This leadership move underlines Everest Group’s intent to sharpen financial discipline and operational oversight in a key growth market for its reinsurance and insurance franchise. Next, we’ll explore how Chalkias’s...

People Inc. has submitted a major cash proposal to acquire NYSE:MGM and take the company private. The MGM board is formally reviewing the offer, signaling an active M&A process. Major insider He Chaolian has fully exited MGM, marking a complete sale of that insider stake. The proposal and insider exit together point to a significant shift in MGM's ownership structure and governance. MGM Resorts International, traded as NYSE:MGM, operates casinos, resorts and entertainment properties,...

Pathward Financial, Inc. recently declared a US$0.05 per-share cash dividend for its third fiscal quarter of 2026, payable on July 1 to shareholders of record as of June 11, and was previously named to Keefe, Bruyette & Woods’ 2026 Bank Honor Roll for consistent 10-year earnings and EPS growth. This combination of a continued dividend and recognition for long-term earnings consistency highlights how management is emphasizing both income returns and execution of its long-term plan. Next,...

BioCryst Pharmaceuticals (BCRX) drew investor attention after presenting new clinical and real world data on its hereditary angioedema therapies ORLADEYO and navenibart at the European Academy of Allergy and Clinical Immunology meeting in Istanbul. See our latest analysis for BioCryst Pharmaceuticals. At a share price of US$9.06, BioCryst has seen short term momentum pick up around the EAACI data, with a 1 day share price return of 4.14% and year to date share price return of 20.80%. However,...

Reverse stock split and governance changes at Marqeta Marqeta (MQ) shareholders have approved a 1-for-4 reverse stock split, a reduction in authorized common and preferred shares, and new officer exculpation provisions under Delaware law, reshaping both the capital structure and governance framework. See our latest analysis for Marqeta. Despite a modest 1-day share price return of 1.57% to US$3.89 and a slightly positive 30-day share price return of 2.10%, Marqeta’s year-to-date share price...

Eaton (ETN) has drawn investor attention after recent performance data showed a past 3 months total return of 11.85% and a 1 year total return of 21.82%, with shares last closing at US$407.06. See our latest analysis for Eaton. Recent trading has added to that picture, with a 4.00% 1 day share price return and an 11.85% 90 day share price return, alongside a 3 year total shareholder return of 121.26%. This suggests momentum has been building over both shorter and longer periods. If Eaton’s...

Citizens recently upgraded EPR Properties (EPR) to Market Outperform, citing the company’s focus on experiential real estate investments, increased investment activity, and more stable theater operations as factors supporting a stronger long-term business profile. See our latest analysis for EPR Properties. The latest upgrade comes after a strong run in the share price, with a year to date share price return of 14.97% and a 3 year total shareholder return of 58.09%. This suggests momentum has...

In recent days, Compass has come under scrutiny after the New York Attorney General opened an antitrust investigation into its acquisition of Anywhere Real Estate, prompting a related securities probe by Pomerantz LLP and sparking heavy options trading activity. This combination of regulatory attention and legal risk is testing the resilience of Compass’s agent-centric, technology-driven brokerage model at a time when its profitability profile and commission-based revenue mix are already...

Vancouver Police Department has become the first police force in Canada to deploy Axon’s Skydio X10 drones. The rollout includes Axon Assistant’s real-time translation and Fleet 3 in-car video with automated recording features. The contract marks an extension of Axon’s public safety technology footprint outside its core U.S. market. For Axon Enterprise (NasdaqGS:AXON), this contract with Vancouver Police Department highlights how the company’s hardware and AI tools are being used together...

Ralph Lauren (RL) has been back in focus after first quarter 2026 results beat Wall Street expectations. In addition, falling oil prices improved the consumer spending backdrop, lifting the stock to a fresh 52 week high. See our latest analysis for Ralph Lauren. The recent first quarter earnings beat and easing energy costs have coincided with strong momentum, with a 30 day share price return of 26.18% and a 1 year total shareholder return of 54.33%. If this kind of consumer strength has your...

Inhibrx Biosciences recently reported that the U.S. FDA accepted for filing its Biologics License Application for ozekibart (INBRX-109) to treat unresectable or metastatic conventional chondrosarcoma, assigning a PDUFA goal date of April 14, 2027 and flagging no filing review issues at this stage. If approved, ozekibart would become the first FDA-approved treatment option for this aggressive bone cancer, addressing a significant unmet medical need highlighted by the positive ChonDRAgon trial...